US 12,391,980 B2
Spatially encoded biological assays
Mark S. Chee, San Diego, CA (US)
Assigned to Prognosys Biosciences, Inc., San Diego, CA (US)
Filed by Prognosys Biosciences, Inc., San Diego, CA (US)
Filed on Mar. 7, 2025, as Appl. No. 19/074,001.
Application 19/074,001 is a continuation of application No. 18/972,148, filed on Dec. 6, 2024, granted, now 12,297,488.
Application 18/972,148 is a continuation of application No. 18/793,359, filed on Aug. 2, 2024, granted, now 12,234,505, issued on Feb. 25, 2025.
Application 18/793,359 is a continuation of application No. 18/100,127, filed on Jan. 23, 2023.
Application 18/100,127 is a continuation of application No. 17/878,519, filed on Aug. 1, 2022, granted, now 11,560,587, issued on Jan. 24, 2023.
Application 17/878,519 is a continuation of application No. 17/556,588, filed on Dec. 20, 2021, granted, now 11,401,545, issued on Aug. 8, 2022.
Application 17/556,588 is a continuation of application No. 17/223,669, filed on Apr. 6, 2021, granted, now 11,208,684, issued on Dec. 28, 2021.
Application 17/223,669 is a continuation of application No. 17/030,230, filed on Sep. 23, 2020, granted, now 11,384,386, issued on Jul. 12, 2022.
Application 17/030,230 is a continuation of application No. 16/988,284, filed on Aug. 7, 2020, granted, now 10,961,566, issued on Mar. 30, 2021.
Application 16/988,284 is a continuation of application No. 16/414,213, filed on May 16, 2019, granted, now 10,787,701, issued on Sep. 29, 2020.
Application 16/414,213 is a continuation of application No. 16/402,098, filed on May 2, 2019, granted, now 10,472,669, issued on Nov. 12, 2019.
Application 16/402,098 is a continuation of application No. 16/276,235, filed on Feb. 14, 2019, granted, now 10,480,022, issued on Nov. 19, 2019.
Application 16/276,235 is a continuation of application No. 15/187,661, filed on Jun. 20, 2016, granted, now 10,308,982, issued on Jun. 4, 2019.
Application 15/187,661 is a continuation of application No. 13/080,616, filed on Apr. 5, 2011, granted, now 9,371,598, issued on Jun. 21, 2016.
Claims priority of provisional application 61/321,124, filed on Apr. 5, 2010.
Prior Publication US 2025/0207183 A1, Jun. 26, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6837 (2018.01); B01L 3/00 (2006.01); C12Q 1/68 (2018.01); C12Q 1/6804 (2018.01); C12Q 1/6809 (2018.01); C12Q 1/6834 (2018.01); C12Q 1/6841 (2018.01); C12Q 1/6869 (2018.01); C12Q 1/6874 (2018.01); C12Q 1/6876 (2018.01); C40B 30/04 (2006.01); C40B 60/04 (2006.01); G01N 33/53 (2006.01); G01N 33/543 (2006.01); G01N 33/68 (2006.01); C12Q 1/6858 (2018.01)
CPC C12Q 1/6837 (2013.01) [B01L 3/502715 (2013.01); C12Q 1/68 (2013.01); C12Q 1/6804 (2013.01); C12Q 1/6809 (2013.01); C12Q 1/6834 (2013.01); C12Q 1/6841 (2013.01); C12Q 1/6869 (2013.01); C12Q 1/6874 (2013.01); C12Q 1/6876 (2013.01); C40B 30/04 (2013.01); C40B 60/04 (2013.01); G01N 33/5308 (2013.01); G01N 33/543 (2013.01); G01N 33/54366 (2013.01); G01N 33/6845 (2013.01); G01N 33/6848 (2013.01); C12Q 1/6858 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2458/10 (2013.01); G01N 2458/40 (2013.01)] 20 Claims
 
1. A method comprising:
(a) providing a substrate comprising a plurality of nucleic acid molecules each having (i) a first sequence configured to bind a target biological molecule in a tissue section, and (ii) a second sequence corresponding to a location on the substrate;
(b) contacting the tissue section with the substrate;
(c) capturing the target biological molecule from the tissue section onto a nucleic acid molecule of the plurality of nucleic acid molecules using the first sequence; and
(d) generating a nucleic acid molecule comprising (i) a sequence of the captured target biological molecule, or a complement thereof, and (ii) the second sequence corresponding to the location on the substrate, or a complement thereof.